Wedbush assumes coverage of Voyager with outperform rating
Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s ...
Wedbush upgrades Voyager to Outperform on pipeline progress
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...
Snowflake Stock Rises as Wedbush Notes AI 'Sweet Spot' in Upgrade
Key Takeaways Wedbush upgraded Snowflake as the analysts predicted that the artificial intelligence software era is ...
Tech Stocks Set For Strong Santa Rally As Wall Street Looks For An End To 'Regulatory Spider Web' In The Trump Era, Says Dan Ives
Major technology stocks are positioned for a strong year-end rally as artificial intelligence initiatives accelerate and ...
Wedbush Upgrades Snowflake Inc. (SNOW) to Outperform with $190 Target, Citing AI-Driven Growth Opportunities
Power needs for artificial intelligence and cloud computing are expanding so rapidly that some data center campuses may use ...
Kioxia, SanDisk filings illustrate value of Western Digital split, says Wedbush
Wedbush notes that in the past two weeks Kioxia filed for an IPO and SanDisk released its 10-12B, telling investors that data from these ...
Tesla's AI Push Could Pave Way for $2 Trillion Valuation, Wedbush Says
A potential Trump administration may ease regulations for self-driving vehicles, accelerating Tesla's progress ...
Tesla Stock Finished Black Friday on a High Note
The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...
Tesla remains the most undervalued AI play amid regulatory shifts, says Wedbush
Tesla’s strategic pivot toward AI and autonomy reinforces its position as a leading disruptive technology company, not merely an automaker, the analysts said. Investors are closely watching regulatory ...
Business Insider3d
Wedbush upgrades Voyager to Outperform on pipeline progress
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company’s tau antibody for ...
Seeking Alpha2d
Wedbush assumes coverage of Voyager with outperform rating
Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s TRACER platform. The investment firm said it believes TRACER alone should ...